

List of Progress in Hematology "Review Series" 2017-2018

*****2018*****

Iron metabolism and the related diseases (Edited by Hideo Harigae)

1. Tomas Ganz T. Iron and infection. *Int J Hematol.* 2017; 107:7-15.
2. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. *Int J Hematol.* 2018; 107:16-30.
3. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. *Int J Hematol.* 2018; 107:31-43.
4. Furuyama K, Kaneko K. Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia. *Int J Hematol.* 2018; 107:44-54.
5. Gattermann N. Iron overload in myelodysplastic syndromes (MDS). *Int J Hematol.* 2018; 107:55-63.

New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation (Edited by Yoshinobu Maeda)

1. Matsuoka K. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives. *Int J Hematol.* 2018; 107:130-7.
2. Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. *Int J Hematol.* 2018; 107:138-50.
3. Elssen CHMJ, Ciurea SO. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? *Int J Hematol.* 2018; 107:151-6.

Advances in immunotherapy for hematological malignancies (Edited by Norimitsu Kadowaki)

1. Mehta RS, Randolph B, Daher M, Rezvani K. NK cell therapy for hematologic malignancies. *Int J Hematol.* 2018; 107: 262-70.
2. Kawamoto H, Masuda K, Nagano S, Maeda T. Cloning and expansion of antigen-specific T cells using iPS cell technology:

development of “off-the-shelf” T cells for the use in allogeneic transfusion settings. *Int J Hematol.* 2018; 107: 271-7.

3. Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. *Int J Hematol.* 2018; 107: 278-85.

Current status and progress of lymphoma research in East Asian countries (Edited by Junji Suzumiya)

1. Yoo KH, Lee H, Suh C. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. *Int J Hematol.* 2018; 107: 395-404.
2. Shi Y. Current status and progress of lymphoma management in China. *Int J Hematol.* 2018; 107: 405-12.
3. Chan JY, Lim ST. Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. *Int J Hematol.* 2018; 107: 413-9.
4. Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. *Int J Hematol.* 2018; 107: 420-7.

The regulatory signal for normal and abnormal hematopoiesis (Edited by Fumio Arai)

1. Sigurdsson V, Miharada K. Regulation of unfolded protein response in hematopoietic stem cells. *Int J Hematol.* 2018; 107:627-33.
2. Wilkinson AC, Yamazaki A. The hematopoietic stem cell diet. *Int J Hematol.* 2018; 107: 634-41.
3. Sugimura R. The significance and application of vascular niche in the development and maintenance of hematopoietic stem cells. *Int J Hematol.* 2018; 107: 642-5.
4. Hosokawa K, Arai F. The role of telomere binding molecules for normal and abnormal hematopoiesis. *Int J Hematol.* 2018; 107: 646-55.

Chronic Myeloid Leukemia (Edited by Yosuke Minami)

1. Rea D, Cayuela J-M. Treatment-free remission in patients with chronic myeloid leukemia. *Int J Hematol.* 2018; 108: 355-64.
2. Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N, Yuda J, et al. Chronic myeloid leukemia stem cells and molecular

target therapies for overcoming resistance and disease persistence. *Int J Hematol.* 2018; 108: 365-70.

2017

Epigenetics in hematological malignancies (Edited by Atsushi Iwama)

1. Yang W, Ernst P. SET/MLL family proteins in hematopoiesis and leukemia. *Int J Hematol.* 2017; 105:7-16.
2. Chiba S. Dysregulation of TET2 in hematologic malignancies. *Int J Hematol.* 2017; 105:17-22.
3. Sashida G, Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. *Int J Hematol.* 2017; 105:23-30.
4. Mazumdar C, Majeti R. The role of mutations in the cohesin complex in acute myeloid leukemia. *Int J Hematol.* 2017; 105:31-6.

Extracellular Molecules in Hematopoietic Stem Cell Mobilisation (Edited by Susan K. Nilsson)

1. Bendall L. Extracellular molecules in hematopoietic stem cell mobilization. *Int J Hematol.* 2017; 105:118-28.
2. Tay J, Levesque JP, Winkler IG. Cellular players of hematopoietic stem cell mobilization in the bone marrow niche. *Int J Hematol.* 2017; 105:129-40.
3. Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. *Int J Hematol.* 2017; 105:141-52.
4. Texier L, Lineburg KE, MacDonald KPA. Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes. *Int J Hematol.* 2017; 105:153-61.

Leukemia stem cell: its target, environment, and genetics (Edited by Fumihiko Ishikawa)

1. Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. *Int J Hematol.* 2017; 105:549-57.
2. Mu L-L, Ke F, Guo X-L, Cai J-J, Hong D-L. Neoplasms in the bone marrow niches: disturbance of the microecosystem. *Int J*

Hematol. 2017; 105:558-65.

3. Camacho V, McClearn V, Patel S, Welner RS. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. *Int J Hematol.* 2017; 105:566-77.

Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects (Edited by Hironori Harada)

1. Itzykson R, Duchmann M, Lucas N, Solary E. CMML: Clinical and molecular aspects. *Int J Hematol.* 2017; 105:711-19
2. Yoshimi A, Abdel-Wahab O. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. *Int J Hematol.* 2017; 105:720-31
3. Makishima H. Somatic SETBP1 mutations in myeloid neoplasms. *Int J Hematol.* 2017; 105:732-42
4. Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. *Int J Hematol.* 2017; 105:743-7

Hematopoietic stem cells (Edited by Hideaki Nakajima)

1. Karigane D, Takubo K. Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions. *Int J Hematol.* 2017; 106:18-26.
2. Takizawa H, Manz MG. Impact of inflammation on early hematopoiesis and the microenvironment. *Int J Hematol.* 2017; 106:27-33.
3. Kunimoto H, Nakajima H. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. *Int J Hematol.* 2017; 106:34-44.
4. Asada N, Takeishi S, Frenette PS. Complexity of bone marrow hematopoietic stem cell niche. *Int J Hematol.* 2017; 106:45-54.

Familial predisposition of myeloid malignancies: Biological and clinical significances of recurrent germline mutations (Edited by Hirotaka Matsui)

1. Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL. Myeloid neoplasms with germline DDX41 mutation. *Int J Hematol.*

2017; 106:163-74.

2. Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM. Heterogeneity of GATA2-related myeloid neoplasms. *Int J Hematol.* 2017; 106:175-82
3. Hayashi Y, Harada Y, Huang G, Harada H. Myeloid neoplasms with germ line RUNX1 mutation. *Int J Hematol.* 2017; 106:183-8.
4. Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. *Int J Hematol.* 2017; 106:189-95.

DNA damage repair network (Edited by Shuki Mizutani)

1. Mizutani S. DNA damage response and disorders with hematology, oncology and immunology. *Int J Hematol.* 2017; 106:326-7.
2. Cheung RS, Taniguchi T. Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers. *Int J Hematol.* 2017; 106:335-44.
3. Takagi M. DNA damage response and hematological malignancy. *Int J Hematol.* 2017; 106:345-56.
4. Morio T. Recent advances in the study of immunodeficiency and DNA damage response. *Int J Hematol.* 2017; 106:357-65.